{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T20:27:37Z","timestamp":1692736057939},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2002,8]]},"DOI":"10.1007\/s11920-996-0045-8","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T21:18:03Z","timestamp":1180732683000},"page":"264-269","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacotherapy of childhood anxiety disorders"],"prefix":"10.1007","volume":"4","author":[{"given":"Christopher J.","family":"Kratochvil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"March","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"45_CR1","first-page":"109","volume-title":"Anxiety Disorders in Children and Adolescents","author":"EJ Costello","year":"1995","unstructured":"Costello EJ, Angold A: Epidemiology. In Anxiety Disorders in Children and Adolescents. Edited by March J. New York: Guilford Press; 1995:109\u2013124."},{"issue":"suppl","key":"45_CR2","doi-asserted-by":"crossref","first-page":"69S","DOI":"10.1097\/00004583-199710001-00006","volume":"36","author":"GA Bernstein","year":"1997","unstructured":"Bernstein GA, Shaw K: Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 1997, 36(suppl):69S-84S. Although published in 1997, this article describes the American Academy of Child and Adolescent Psychiatry\u2019s most recent practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. Practical and clinically useful information is reviewed and summarized.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"45_CR3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","volume":"344","author":"Research Unit on Pediatric Psychopharmacology Anxiety Study Group","year":"2001","unstructured":"Research Unit on Pediatric Psychopharmacology Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001, 344:1279\u20131285. Double blind, placebo-controlled, randomized trial of fluvoxamine in 128 youths with social phobia, separation anxiety disorder, or generalized anxiety disorder. Well-designed study taking a practical approach of combining several anxiety disorders that typically occur together. Demonstrated that fluvoxamine is an effective treatment for children and adolescents these anxiety disorders.","journal-title":"N Engl J Med"},{"key":"45_CR4","first-page":"155","volume":"34","author":"LL Greenhill","year":"1998","unstructured":"Greenhill LL, Pine D, March J, et al.: Assessment issues in treatment research of pediatric anxiety disorders: what is working, what is not working, what is missing, and what needs improvement. Psychopharmacol Bull 1998, 34:155\u201364.","journal-title":"Psychopharmacol Bull"},{"key":"45_CR5","unstructured":"Walkup J, Davies M: The Pediatric Anxiety Rating Scale (PARS): a reliability study. Scientific proceedings of the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; Chicago, IL. October 23, 1999;"},{"key":"45_CR6","volume-title":"ECDEU Assessment Manual for Pharmacotherapy","author":"W Guy","year":"1976","unstructured":"Guy W: ECDEU Assessment Manual for Pharmacotherapy. Rockville: US Department of Health, Education and Welfare; 1976."},{"key":"45_CR7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archpsyc.1995.03950130053006","volume":"52","author":"JH Greist","year":"1995","unstructured":"Greist JH, Jefferson JW, Kobak KA, et al.: Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder: a meta-analysis. Arch Gen Psych 1995, 52:53\u201360.","journal-title":"Arch Gen Psych"},{"issue":"suppl","key":"45_CR8","first-page":"22","volume":"60","author":"MR Liebowitz","year":"1999","unstructured":"Liebowitz MR: Update on the diagnosis and treatment of social anxiety disorder. J Clin Psych 1999, 60(suppl):22\u201326.","journal-title":"J Clin Psych"},{"key":"45_CR9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/(SICI)1520-6394(1998)7:3<134::AID-DA7>3.0.CO;2-B","volume":"7","author":"MB Stein","year":"1998","unstructured":"Stein MB: Medication treatments for panic disorder and social phobia. Depress Anxiety 1998, 7:134\u2013138.","journal-title":"Depress Anxiety"},{"key":"45_CR10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","volume":"283","author":"K Brady","year":"2000","unstructured":"Brady K, Pearstein T, Asnis GM, et al.: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000, 283:1837\u20131844.","journal-title":"JAMA"},{"key":"45_CR11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","volume":"40","author":"MA Riddle","year":"2001","unstructured":"Riddle MA, Reeve EA, YarYura-Tobias JA, et al.: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001, 40:222\u2013229. Double blind, randomized, placebo-controlled trial of fluvoxamine in 120 youths with OCD. Demonstrated a rapid onset of action, with a separation from placebo at 1 week.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"45_CR12","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00004583-199706000-00023","volume":"36","author":"L Scahill","year":"1997","unstructured":"Scahill L, Riddle MA, McSwiggin-Hardin M, et al.: Children\u2019s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997, 36:844\u2013852.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"45_CR13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-200107000-00011","volume":"40","author":"DA Geller","year":"2001","unstructured":"Geller DA, Hoog SL, Heiligenstein JH, et al.: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001, 40:773\u2013779. Double blind, randomized, placebo-controlled trial of fluoxetine in youths with OCD. Demonstrated fluoxetine to be effective and welltolerated in the treatment of OCD in this population.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"45_CR14","unstructured":"Geller DA, Heiligenstein J, Hoog S, et al.: Predictive factors in response to fluoxetine treatment for pediatric OCD. Scientific proceedings of the 48th Annual American Academy of Child & Adolescent Psychiatry; Honolulu, HI. October 23\u201328, 2001;"},{"key":"45_CR15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00004583-200108000-00010","volume":"40","author":"PH Thomsen","year":"2001","unstructured":"Thomsen PH, Ebbesen C, Persson C: Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry 2001, 40:895\u2013902. Although this is an open-label trial of citalopram in OCD, it is important in that it followed 30 adolescents with OCD for 1 to 2 years while on treatment. Subjects continued to show incremental improvement throughout the first year of treatment, with 70% meeting efficacy criteria after 1 year. All subjects did receive 10 to 26 sessions of CBT in addition to pharmacotherapy.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"45_CR16","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmusen SA, et al.: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989, 46:1006\u20131011.","journal-title":"Arch Gen Psychiatry"},{"key":"45_CR17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00004583-200110000-00011","volume":"40","author":"EH Cook","year":"2001","unstructured":"Cook EH, Wagner KD, March JS, et al.: Long-term sertraline treatment of children and adolescents with obsessivecompulsive disorder. J Am Acad Child Adolesc Psychiatry 2001, 40:1175\u20131181. Trials following \"long-term\" treatment are limited in Child Psychiatry, making this study an important contribution to the field. This 52-week study followed 72 children and 65 adolescents with OCD who had responded to an acute trial of sertraline. Concomitant psychotherapy was allowed. Response rates at endpoint were 72% for children and 61% for adolescents.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"45_CR18","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","volume":"280","author":"JS March","year":"1998","unstructured":"March JS, Biederman J, Wolkow R, et al.: Sertraline in children and adolescents with obsessive-compulsive behavior: a multicenter randomized controlled trial. JAMA 1998, 280:1752\u20131756.","journal-title":"JAMA"},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1176\/appi.ajp.158.12.2008","volume":"158","author":"MA Rynn","year":"2001","unstructured":"Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001, 158:2008\u20132014. This double blind, randomized, placebo controlled trial of 22 children and adolescents evaluated the use of sertraline in the treatment of generalized anxiety disorder. The study demonstrated a statistically significant response to treatment for these youths on all five primary efficacy scales.","journal-title":"Am J Psychiatry"},{"key":"45_CR20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959, 32:50\u201355.","journal-title":"Br J Med Psychol"},{"key":"45_CR21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00004583-200105000-00016","volume":"40","author":"SN Compton","year":"2001","unstructured":"Compton SN, Grant PJ, Chrisman AK, et al.: Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001, 40:564\u2013571.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"45_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/104454601750284054","volume":"11","author":"G Masi","year":"2001","unstructured":"Masi G, Toni C, Mucci M, et al.: Paroxetine in child and adolescent outpatients with panic disorder. J Child Adolesc Psychopharmacol 2001, 11:151\u2013157.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"45_CR23","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJM200104263441711","volume":"344","author":"JT Coyle","year":"2001","unstructured":"Coyle JT: Drug treatment of anxiety disorders in children. N Engl J Med 2001, 344:1326\u20131327.","journal-title":"N Engl J Med"},{"issue":"suppl","key":"45_CR24","first-page":"1","volume":"58","author":"J March","year":"1997","unstructured":"March J, Frances A, Kahn D, Carpenter D: Expert consensus guidelines: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997, 58(suppl):1\u201372.","journal-title":"J Clin Psychiatry"},{"key":"45_CR25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-1-4615-4755-6_18","volume-title":"Handbook of Psychotherapies with Children and Families","author":"C Kratochvil","year":"1999","unstructured":"Kratochvil C, Kutcher S, Reiter S, March J: Pharmacotherapy of pediatric anxiety disorders. In Handbook of Psychotherapies with Children and Families. Edited by Russ S, Ollendick T. New York: Plenum; 1999:345\u2013366."},{"key":"45_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1022682723027","volume":"26","author":"JS March","year":"1998","unstructured":"March JS, Curry JF: Predicting the outcome of treatment. J Abnorm Child Psychol 1998, 26:39\u201351.","journal-title":"J Abnorm Child Psychol"},{"key":"45_CR27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1005174913412","volume":"28","author":"KC Wells","year":"2000","unstructured":"Wells KC, Pelham WE, Kotkin RA, et al.: Psychosocia treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol 2000, 28:483\u2013505.","journal-title":"J Abnorm Child Psychol"},{"key":"45_CR28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1056-4993(18)30138-X","volume":"9","author":"J Velosa","year":"2000","unstructured":"Velosa J, Riddle M: Pharmacologic treatment of anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin North Am 2000, 9:119\u2013133.","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"45_CR29","doi-asserted-by":"crossref","unstructured":"Williams T, Hodgman C: Medication for the management of anxiety disorders in children and adolescents. Pediatr Ann 30:146\u2013153.","DOI":"10.3928\/0090-4481-20010301-08"},{"key":"45_CR30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1097\/00004583-199511000-00012","volume":"34","author":"HL Leonard","year":"1997","unstructured":"Leonard HL, March J, Rickler KC, Allen AJ: Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatr 1997, 34:1460\u20131468.","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"45_CR31","first-page":"35","volume":"34","author":"B Birmaher","year":"1998","unstructured":"Birmaher B: Should we use antidepressant medications for children and adolescents with depressive disorders? Psychopharmacol Bull 1998, 34:35\u201339.","journal-title":"Psychopharmacol Bull"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-996-0045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-996-0045-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-996-0045-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:47:02Z","timestamp":1559436422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-996-0045-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s11920-996-0045-8","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}